Recent Developments in Targeting Access to High Cost Medicines in Australia
- Topics:
- Healthcare Services,
- Pharmeceuticals
- Tags:
- Australia,
- Office Suites,
- Microsoft Office,
- Microsoft Access,
- Medicine,
- Enterprise Software,
- Databases,
- Data Management,
- BioMed Central,
- Software
- Source:
- BioMed Central
FREE Registration is required
Overview: In Australia, the Pharmaceutical Benefits Scheme (PBS) has developed a set of arrangements to control access to high-cost medicines to ensure their use is cost-effective. These medicines include the Tumour Necrosis Factor-Alpha Inhibitors (TNFIs) for the treatment of rheumatoid arthritis. The aim of this study was to explore basic views on the restricted access to TNFIs in order to confirm where further investigation should take place in the next phase. This first phase highlighted a range of issues associated with the PBS arrangements restricting access to TNFIs. Timely review and report of issues and concerns associated with such policy developments that arose in practice are essential.
(Is this item miscategorized? Does it need more tags? Let us know.)
Format: PDF | Size: 141KB | Date: Nov 2005 | Pages: 25



